摘要
目的:观察生血宝合剂联合重组人促红细胞生成素(rhu-EPO)治疗肿瘤化疗相关性贫血的临床疗效及安全性。方法:选取2017年1月-2019年1月本院收治的实体瘤及经化疗后出现中重度贫血患者72例。按随机数字表法分为对照组及观察组,各36例。对照组予以rhu-EPO治疗,观察组在对照组基础上加用生血宝合剂进行联合治疗。比较两组临床疗效、治疗前后血常规指标水平、生活质量、不良反应发生情况。结果:观察组总有效率为94.44%,显著高于对照组的75.00%,差异有统计学意义(χ^2=5.18,P<0.05);治疗后,观察组RBC、Hb水平升高较对照组更为显著(P<0.05);观察组生活质量总体改善率97.22%,高于对照组的75.00%,差异有统计学意义(P<0.05);观察组不良反应发生率8.33%,低于对照组的11.11%,差异无统计学意义(P>0.05)。结论:生血宝合剂联合rhu-EPO治疗肿瘤化疗相关性贫血具有较好的临床疗效,可有效提高患者RBC、Hb水平,改善患者的生活质量,且无明显不良反应。
Objective:To explore the clinical efficacy and safety of Shengxuebao Mixture combined with Recombinant Human Erythropoietin(rhu-EPO)for treatment of tumor chemotherapy-related anemia.Method:A total of 72 cases of solid tumors and moderate to severe anemia after chemotherapy from 2017 to January 2019 in our hospital were selected.According to the random number table method,the patients were divided into the control group and the observation group,36 cases in each group.The control group was given rhu-EPO,and the observation group was given Shengxuebao Mixture on the basis of the control group.The clinical efficacy,blood routine indexes before and after treatment,quality of life and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was 94.44%,which was significantly higher than 75.00%of the control group,the difference was statistically significant(χ^2=5.18,P<0.05).After treatment,the levels of RBC and Hb in the observation group increased more significantly than those in the control group(P<0.05).The overall improvement rate of quality of life in the observation group was 97.22%,which was higher than 75.00%in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 8.33%,which was lower than 11.11%in the control group,the difference was not statistically significant(P>0.05).Conclusion:Shengxuebao Mixture combined with rhu-EPO has good clinical efficacy in the treatment of cancer chemotherapy-related anemia,it can effectively improve the level of RBC and Hb,improve the quality of life of patients and without obvious adverse reactions.
作者
陈小妹
刘勇
CHEN Xiaomei;LIU Yong(Ganzhou Cancer Hospital, Ganzhou 341000, China)
出处
《中国医学创新》
CAS
2019年第30期65-69,共5页
Medical Innovation of China
